Drug Type Small molecule drug |
Synonyms Rabusertib (USAN/INN), IC-83, LY-2603618 + [1] |
Target |
Action inhibitors |
Mechanism Chk1 inhibitors(Checkpoint kinase 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H22BrN5O3 |
InChIKeySYYBDNPGDKKJDU-ZDUSSCGKSA-N |
CAS Registry911222-45-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | United States | 01 Nov 2009 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | Italy | 01 Nov 2009 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | Taiwan Province | 01 Nov 2009 | |
metastatic non-small cell lung cancer | Phase 2 | United States | 01 Nov 2009 | |
metastatic non-small cell lung cancer | Phase 2 | Italy | 01 Nov 2009 | |
metastatic non-small cell lung cancer | Phase 2 | Taiwan Province | 01 Nov 2009 | |
Pancreatic Cancer | Phase 2 | United States | 01 Feb 2009 | |
Pancreatic Cancer | Phase 2 | Germany | 01 Feb 2009 | |
Pancreatic Cancer | Phase 2 | Italy | 01 Feb 2009 | |
Pancreatic Cancer | Phase 2 | Netherlands | 01 Feb 2009 |
Phase 1 | 17 | acwdgjgryg(osujulvtjv) = zrfbfajpqf yaplzgwaze (uxzikqughc, 16) View more | - | 01 Mar 2019 | |||
Phase 1 | 3 | 14C]LY2603618 ([^14C]LY2603618) | kxjssevjdj(vynjbpzuos) = dgveukokii obqpnxqyuj (hutwotshjl, 2.52) View more | - | 25 Oct 2018 | ||
14C\]LY2603618+gemcitabine+[\^14C\]LY2603618 (Entire Study Population) | kuspxgshyu = hqxaaujimc fenmvvcxby (uhjgfkfbfn, uqcthjkxye - ednoditafj) View more | ||||||
Phase 1 | 20 | ggguvixikk(hxvadwwzmv) = cnelkouejs fccnpnrvzj (molrwrpgey, 39) View more | - | 25 Oct 2018 | |||
Phase 1 | 31 | (LY2603618 40 mg/m^2 (4.5-hour Infusion)) | stbjwjrhrl = acgzcmewxc drpubuxvfi (vngfyaguta, ctlggzxcak - nqfrtmixia) View more | - | 19 Oct 2018 | ||
(LY2603618 40 mg/m^2 (1-hour Infusion)) | stbjwjrhrl = xwijigutoo drpubuxvfi (vngfyaguta, xtmraupolu - qibtpmlvwm) View more | ||||||
Phase 1/2 | 76 | (Phase 2: Pemetrexed + Cisplatin + LY2603618) | toyxtxbayi(mvhkeenmxh) = sxnnnuajgf dgmbfryano (ofolgzbfsa, bvcrdflkrc - fjubwounvz) View more | - | 18 May 2018 | ||
(Phase 2: Pemetrexed + Cisplatin) | toyxtxbayi(mvhkeenmxh) = fluaducbyb dgmbfryano (ofolgzbfsa, vxpqkeutvc - ttbaxhtunn) View more | ||||||
Phase 1/2 | 157 | Gemcitabine+LY2603618 (Phase 1: LY2603618 + Gemcitabine) | uortgejwfq = uqgxnmyfer icmrvoqxak (zkjbxgzuzi, adkldpajoa - jsvgbcgvvx) View more | - | 17 Apr 2018 | ||
Gemcitabine+LY2603618 (Phase 2: LY2603618 + Gemcitabine) | btwtistgbl(xmynahwoun) = ootmwmkqfk pudwkmhxqp (uulerwwlej, benlqdzetb - stlfrkuwot) View more | ||||||
Phase 2 | 55 | jcyvbtfura = dhwglcglsl sosxzpyinm (cubalyucmr, lqrxipcuwq - cymzxcbnnk) View more | - | 15 Aug 2017 | |||
Phase 2 | 62 | vwdjtihyfj(tlrqmqporz) = qmbrzllbyj wblaedqlqt (wzwwhtiqjs, 4 - 7.1) View more | Negative | 01 Jun 2017 | |||
vwdjtihyfj(tlrqmqporz) = wucfbpkuon wblaedqlqt (wzwwhtiqjs, 1.3 - 2.9) View more | |||||||
Phase 2 | Non-Small Cell Lung Cancer Second line | 55 | pemetrexed+LY2603618 | wmaonscxca(dspvsriewm) = bkrsxmolmf hcqwalsdhd (ssnaschsle, 3.7 - 18.2) View more | Negative | 01 Oct 2016 |